Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZYNE Stock Summary
- Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.07% of US listed stocks.
- With a price/sales ratio of 1,661.62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99.79% of stocks in our set.
- The volatility of Zynerba Pharmaceuticals Inc's share price is greater than that of 93.47% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Zynerba Pharmaceuticals Inc, a group of peers worth examining would be BPMX, RVNC, ADVM, PSTI, and PRTA.
- Visit ZYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.zynerba.com.
ZYNE Stock Price Chart Interactive Chart >
ZYNE Price/Volume Stats
| Current price | $3.87 | 52-week high | $9.00 |
| Prev. close | $4.13 | 52-week low | $3.15 |
| Day low | $3.81 | Volume | 4,533,800 |
| Day high | $4.07 | Avg. volume | 2,777,749 |
| 50-day MA | $4.19 | Dividend yield | N/A |
| 200-day MA | $4.58 | Market Cap | 159.65M |
Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio
Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.
Latest ZYNE News From Around the Web
Below are the latest news stories about Zynerba Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in OctoberDEVON, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being held virtually October 21-25, 2021, and the 68th American Academy of Child & Adolescent Psychiatry Annual Meeting, being held virtually October 18- |
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough SummitDEVON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held virtually October 18-19, 2021. A copy of the poster titled, “RECONNECT (ZYN2-CL-033): Design of a Phas |
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & ExhibitionDEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibition, which will be held virtually from October 8-11, 2021. A copy of the poster titled, “Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol |
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare ConferenceDEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET. |
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome - ZynerbaTrial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announces the initiation of [] |
ZYNE Price Returns
| 1-mo | -14.57% |
| 3-mo | -14.19% |
| 6-mo | -14.00% |
| 1-year | 4.03% |
| 3-year | -32.70% |
| 5-year | -67.48% |
| YTD | 17.27% |
| 2020 | -45.36% |
| 2019 | 103.37% |
| 2018 | -76.28% |
| 2017 | -19.69% |
| 2016 | 54.82% |
Continue Researching ZYNE
Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...